Harbin Pharmaceutical Group Co (SHSE:600664) Ending Cash Position : ¥2,797 Mil (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co Ending Cash Position?

Harbin Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥2,797 Mil.

Harbin Pharmaceutical Group Co's quarterly Ending Cash Position increased from Sep. 2023 (¥2,680 Mil) to Dec. 2023 (¥2,956 Mil) but then declined from Dec. 2023 (¥2,956 Mil) to Mar. 2024 (¥2,797 Mil).

Harbin Pharmaceutical Group Co's annual Ending Cash Position increased from Dec. 2021 (¥1,191 Mil) to Dec. 2022 (¥2,064 Mil) and increased from Dec. 2022 (¥2,064 Mil) to Dec. 2023 (¥2,956 Mil).

Harbin Pharmaceutical Group Co Ending Cash Position Historical Data

The historical data trend for Harbin Pharmaceutical Group Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Pharmaceutical Group Co Ending Cash Position Chart

Harbin Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

640.70

871.92

1,191.46

2,064.25

2,956.14

Harbin Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															2,295.47	2,539.95	2,679.59	2,956.14	2,796.70

Harbin Pharmaceutical Group Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Harbin Pharmaceutical Group Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2064.246	+	891.893
	=	2,956

Harbin Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2956.138	+	-159.437
	=	2,797

Harbin Pharmaceutical Group Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Harbin Pharmaceutical Group Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Pharmaceutical Group Co (SHSE:600664) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » Ending Cash Position

Traded in Other Exchanges

N/A

Address

Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018

Website

http://www.hayao.com

Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.

Executives

Lin Guo Ren	senior management
Wang Hai Sheng	senior management
Liu Bo	senior management
Meng Xiao Dong	senior management
Xu Hai Ying	Directors, senior managers
Liang Chen	senior management
Wang Peng Hao	senior management
Xiao Qiang	senior management
Wei Shuang Ying	senior management
Zhou Xing	senior management
Bian Ke	Supervisors
Sha Mei	senior management
Jian Shi Hui Zhu Xi	Supervisors
Wang Zhi Fu	Supervisors
Jiang Lu	Director

Harbin Pharmaceutical Group Co (SHSE:600664) Headlines

No Headlines